Global Leading Market Research Publisher QYResearch announces the release of its latest report “Traditional In Vitro Fertilization – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Traditional In Vitro Fertilization market, including market size, share, demand, industry development status, and forecasts for the next few years.
The global market for Traditional In Vitro Fertilization was estimated to be worth US1.8billionin2025andisprojectedtoreachUS1.8billionin2025andisprojectedtoreachUS 2.9 billion by 2032, growing at a CAGR of 7.0% from 2026 to 2032.
For reproductive endocrinologists, embryologists, and fertility specialists, the core assisted reproductive technology (ART) process challenge is precise: combining mature oocytes (retrieved via transvaginal ultrasound-guided follicular aspiration after controlled ovarian hyperstimulation (COH)) with prepared sperm (sperm washing, density gradient centrifugation, swim-up) in a defined embryo culture medium (sequential or single-step) to facilitate fertilization (co-incubation for 12-18 hours), promote embryo development to blastocyst stage (Day 5-6, inner cell mass (ICM), trophectoderm), and select high-quality embryos for transfer (fresh (ET) or frozen (FET)) based on morphological grading (Gardner, ASRM grade), achieving high fertilization rates (70-80%), implantation rates (30-50% per embryo), and live birth rates (40-55% per cycle), while minimizing multiple gestations (elective single embryo transfer (eSET)) and avoiding ovarian hyperstimulation syndrome (OHSS). The solution lies in traditional in vitro fertilization (IVF)—standard insemination method (co-incubation of oocytes with motile sperm) as opposed to intracytoplasmic sperm injection (ICSI) (single sperm injected directly). Traditional IVF is preferred for mild male factor infertility, unexplained infertility, endometriosis, ovulatory disorders, tubal factor, and when sperm parameters are normal (WHO criteria: concentration >15 million/mL, motility >40%, morphology >4% normal forms). Since the first IVF baby (1978, Louise Brown), the global IVF market has grown substantially, driven by rising infertility (1 in 6 couples worldwide), delayed childbearing, social acceptance, and insurance coverage.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/5984804/traditional-in-vitro-fertilization
1. Industry Segmentation by Media Type and End-User
The Traditional In Vitro Fertilization market is segmented as below by Type:
- Embryo Culture Media – 38% market share (2025). Sequential media (Day 1-3, Day 3-5/6) vs single-step (continuous culture). Amino acids (glutamine, non-essential), energy substrates (pyruvate, glucose), human serum albumin (HSA), antibiotics (gentamicin).
- Cryopreservation Media (vitrification) – 32% market share. High concentrations of cryoprotectants (ethylene glycol, DMSO (dimethyl sulfoxide), sucrose), non-permeating (trehalose). For embryo vitrification (slow freezing obsolete) and oocyte cryopreservation (egg freezing).
- Sperm Processing Media – 18% market share. Density gradient (silica nanoparticles, iodixanol), wash medium (HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) + HSA), swim-up medium.
- Ovum Processing Media – 12% market share (follicular fluid, oocyte collection, washing, holding).
By Application – Fertility Clinics (ART centers, private IVF clinics) leads with 78% market share. Hospitals (academic medical centers, hospital-based fertility programs) 18% share. Others (egg banks, sperm banks, research labs) 4% share.
Key Players – IVF clinics (service providers): HealthPlus Fertility & Women’s Health Center (UAE), Thuriah Medical Center (UAE), Fakih IVF Fertility Center (Middle East), ART Fertility Clinics (India), New Hope IVF (Bahrain), AlReem Medical Center (UAE), Wara Hospital (Kuwait), Royale Hayat Hospital (Kuwait), Quttainah Specialized Hospital (UAE), The Feto Maternal Medical Centre (Oman), Elite Medical Center (Bahrain), Bahrain Gynecology and Infertility Center, Al Baraka Fertility Hospital (Bahrain). (Note: This market segmentation (clinics) versus Media manufacturers (CooperSurgical, Vitrolife, Cook Medical, Fujifilm Irvine Scientific, Vitromed, Kitazato, Progyny, Origio) not listed.)
2. Technical Challenges: Embryo Culture Optimization, Cryopreservation, and Multiple Pregnancy Prevention
Embryo culture to blastocyst — Extended culture Day 5/6 improves uterine-embryo synchrony, higher implantation potential. Requires stable incubator (tri-gas, 5-6% CO₂, 5% O₂, 37°C), time-lapse monitoring (morphokinetics, timing of cleavage, multinucleation, fragmentation).
Cryopreservation (vitrification) — Rapid cooling (>20,000°C/min) prevents ice crystal formation. Warming rate >20,000°C/min. Survival rate >95%.
Elective Single Embryo Transfer (eSET) — Transfer one euploid blastocyst (PGT-A (preimplantation genetic testing for aneuploidy)) reduces multiple gestation (twins, triplets) risk (preterm birth, low birth weight, preeclampsia, gestational diabetes).
3. Policy, User Cases & Technology Trends (Last 6 Months, 2025-2026)
- ASRM (American Society for Reproductive Medicine) (2025) guideline – ICSI vs conventional IVF (no benefit if sperm normal). Traditional IVF recommended.
- ESHRE (European Society of Human Reproduction and Embryology) (2025) – Blastocyst transfer vs cleavage stage (Day 2-3) higher live birth rate.
- CDC (Centers for Disease Control and Prevention) ART Report (2025) – Annual national data for IVF cycles (live birth rate per transfer: 50% <35 y, 40% 35-37 y, 30% 38-40 y, 20% 41-42 y, 5% 43-44 y).
User Case – Unexplained infertility (36 y, 2 years trying) — Ovarian stimulation (antagonist protocol, gonadotropin (FSH (follicle-stimulating hormone) 150 IU)) → 15 oocytes retrieved → 12 mature → 8 fertilized (conventional IVF) → 5 blastocysts (Day 5) → 1 fresh embryo transfer (live birth). 4 vitrified (FET). Process 6 weeks.
4. Exclusive Observation: In Vitro Maturation (IVM) vs Traditional IVF
IVM (immature oocytes retrieved, matured in vitro) avoids ovarian hyperstimulation syndrome (OHSS). Lower success rates. Alternative to traditional IVF for PCOS (polycystic ovary syndrome) patients.
5. Outlook & Strategic Implications (2026-2032)
Through 2032, the traditional IVF market will segment: embryo culture (media) — 40% value, 7% CAGR; cryopreservation (vitrification media) — 30% value, 7-8% CAGR; sperm/ovum processing media — 30% value, 6-7% CAGR. Key success factors: live birth rate (%), blastocyst formation rate (%), implantation rate (%), and multiple pregnancy rate (%). Suppliers who fail to transition from slow freezing to vitrification — and who cannot provide time-lapse incubators — will lose IVF lab market share.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
